At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Dalantercept +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Evaluation of Dalantercept (NSC #757172), a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
In Brief
A Phase 2 clinical trial evaluating Dalantercept and Laboratory Biomarker Analysis for Recurrent Fallopian Tube Carcinoma and 2 related conditions. Completed, enrolled 30 participants across 40 sites.
Detailed Summary
This phase II trial studies the side effects and how well dalantercept works in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer that has returned. Dalantercept may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Dalantercept may also stop the growth of tumor cells by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartNov 2012
Primary CompletionOct 2015
Study CompletionFeb 2019
TodayJul 2026
First PostedNov 2, 2012
Enrollment StartNov 5, 2012
Primary CompletionOct 31, 2015
Study CompletionFeb 19, 2019
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 13.7 years ago
Interventions
Dalanterceptbiological
Given SC
Laboratory Biomarker Analysisother
Correlative studies